Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
On improving DLBCL outcomes, single-agent regimens fall short
Single-agent regimens are most likely not efficient enough to substantially improve outcomes of DLBCL patients.
News
COVID boosters help protect blood cancer patients, but some still vulnerable
Some patients with hematologic malignancies who are seronegative after a full course of COVID-19 vaccination may benefit from a booster.
News
Response to preop immunotherapy predicts survival in early NSCLC
For each 10% increase of residual viable tumor, risk of death was increased 64% and risk of recurrence was increased 71%.
News
Studies confirm survival benefit with postchemoradiotherapy consolidation in NSCLC
The findings show a progression-free survival benefit in patients who underwent concurrent or sequential chemoradiotherapy giving insight to real-...
News
Study supports chemotherapy with immunotherapy for some never-smokers with lung cancer
Although patients with PD-L1 expression below 50% derive clear benefit from combination versus single-agent therapy, treatment selection overall...
News
First-line bevacizumab-osimertinib disappoint in EGFR-mutant NSCLC
The combination provided no added progression-free survival benefit over osimertinib monotherapy for EGFR-mutated nonsquamous NSCLC, but raised...
News
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
News
Breast density associated with increased invasive breast cancer risk after age 65
Breast density and life expectancy should be considered together when making decisions about mammography screening in older women.
News
Combo treatment for NSCLC with brain metastases extends survival by two years for some
The progression-free survival findings are similar to those of a related trial that also showed improved outcomes with pembrolizumab plus...
News
FDA approves neoadjuvant pembro for triple-negative breast cancer
It is the first immunotherapy regimen to be approved for high-risk early-stage triple negative breast cancer.
News
FDA warns of higher death risk with Pepaxto in multiple myeloma
The FDA also hinted at “a future public meeting to discuss the safety findings and explore the continued marketing of Pepaxto,” which has a price...
News
Latest FDA pembrolizumab approval expands label to cutaneous SCCs
The objective response rate in 54 patients with locally advanced disease was 50%, including a complete response rate of 17% and a partial response...